CTLA4 and melanoma: Next, we evaluated the Hugo et al 14cohort (anti-PD1, 25 melanoma patients with complete data), the Riaz et al15 cohort (anti-PD1/anti-CTLA4, 49 melanoma patients with complete data), and the Kim et al16 cohort (anti-PD1, 43 gastric cancer patients with complete data).